Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report

Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising

“…Psoriasis is a chronic, noninfectious, relapsing inflammatory skin disease characterized by genetic, immunitary and environmental factors, associated with social discomfort and psychological disorders affecting 1% to 3% of the Caucasian population. 1,2 Various therapies have been proposed for the treatment of psoriasis, from topical treatments based on corticosteroids and vitamin D derivatives to systemic agents and biological drugs 3 In conclusion, the key role of the IL-23/T17 axis in psoriasis, the efficacy maintained over time, the relatively infrequent dosage regimen and its safety profile make Risankizumab a valid therapeutic choice for patients affected by moderate to severe psoriasis.…”

“…Psoriasis is a chronic, noninfectious, relapsing inflammatory skin disease characterized by genetic, immunitary and environmental factors, associated with social discomfort and psychological disorders affecting 1% to 3% of the Caucasian population 1,2 . Various therapies have been proposed for the treatment of psoriasis, from topical treatments based on corticosteroids and vitamin D derivatives to systemic agents and biological drugs 3 derivatives.…”

Acrodermatitis continua Hallopeau successfully treated by risankizumab

“…Acrodermatitis continua of Hallopeau (ACH) is rare pustular dermatosis, also known as dermatitis repens. It is characterized by chronic recurrent eruptions of sterile pustules on distal parts of the fingers and toes, sometimes accompanied by paronychia 1 . Untreated, the condition may lead to atrophic skin changes, onychodystrophy, and sometimes even disfigurement of the distal phalanges or toes.…”

“…A number of therapies, including oral PUVA, acitretin, methotrexate, and most recently cyclosporine, failed to stabilize this deterioration. Based on recent reports of successful therapy of ACH with some biologics, 1,2 we decided to treat her with risankizumab.…”

Brodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau

“…and approved for the treatment of moderate to severe plaque psoriasis, has been recently used with success in two cases of ACH. 6,7 Here, we describe the third case of ACH treated with brodalumab, which proved to be highly effective even after failure of secukinumab. There was no evidence of underlying neoplasia.…”